



an Open Access Journal by MDPI

Advances in Antifungal Development: Discovery of New Drugs and Drug Repurposing

Guest Editors:

Dr. Jong Heon Kim

Foodborne Toxin Detection and
Prevention Research Unit,
Western Regional Research
Center, USDA-ARS, 800 Buchanan
St., Albany, CA 94710, USA

Dr. Luisa W. Cheng

Foodborne Toxin Detection and
Prevention Research Unit,
Western Regional Research
Center, USDA-ARS, 800 Buchanan
St., Albany, CA 94710, USA

Dr. Kirkwood Land

Department of Biological
Sciences, University of the
Pacific, Stockton, CA 95211, USA

Deadline for manuscript
submissions:

closed (19 November 2021)

Message from the Guest Editors

Current antifungal interventions have often exhibited limited efficacy in treating fungal infections, partly because the development of new antifungal drugs has become stagnant. Only three classes of antifungal drugs are used in clinical settings, namely, azoles, polyenes, and echinocandins; azoles and polyenes were introduced in 1980, while the echinocandin caspofungin was approved for the clinical uses after 2000. Meanwhile, an alternative drug discovery strategy termed drug repurposing has been explored recently. Antifungal drug repurposing is the repositioning process of already marketed pharmaceutical drugs previously approved for curing human diseases such as cardiovascular diseases, arthritis, atherosclerosis, etc., to control fungal infections. One of the advantages of drug repurposing is that the mechanisms of action or safety of the drugs have been well-characterized.

This Special Issue will discuss recent advances in the field of antifungal drug discovery or repurposing with hopes of enhancing the efficiency of current antifungal interventions and identifying new antifungal drugs or alternatives.



mdpi.com/si/56338

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com